5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes.

Anja L GawlitzaJohanna SpeithJenny RinkeRoman SajzewElena K MüllerVivien SchäferAndreas HochhausThomas Ernst

Published in: Journal of cancer research and clinical oncology (2019)

A response to Aza is not associated with eradication of malignant clones, but rather with a stabilization of the clonal architecture. We suggest changes in CpG methylation levels of EZH2 and NOTCH1 as potential targets of epigenetic response to Aza treatment which may also serve as useful biomarkers after clinical evaluation.

Keyphrases

dna methylation
clinical evaluation
genome wide
gene expression
cell proliferation
long non coding rna
long noncoding rna
human health
risk assessment